Pulmonology

Reports of high-impact pulmonology studies by medical professionals

Dexmedetomidine and propofol had similar outcomes in septic, mechanically ventilated adults

1. Treatment with dexmedetomidine was shown not to differ from propofol treatment in adult patients with sepsis who were under mechanical ventilation. 2. No significant...

Epidemiological and virological characteristics of respiratory tract infections in children during COVID-19 outbreak

1. In a large cohort of children from China, there was a significant decrease in outpatient visits and respiratory tract infections during the COVID-19...

Comparative outcomes between COVID-19 and influenza patients placed on veno-venous extracorporeal membrane oxygenation

1. COVID-19 patients with severe ARDS on veno-venous extracorporeal membrane oxygenation were nearly three times as likely to experience in-hospital death compared with influenza...

Use of bamlanivimab for patients with mild to moderate COVID-19 infection

1. Patients from a large academic medical center with mild to moderate COVID-19 in receipt of the monoclonal antibody bamlanivimab had a lower 30-day...

Initial effects of COVID-19 on patients with end-stage kidney disease

1. Patients with end-stage kidney disease were at increased risk of COVID-19-related mortality, particularly among non-Hispanic Black patients. Evidence Rating Level: 3 (Average) End-stage kidney disease...

Mood disorders and outcomes of COVID-19 hospitalizations

1. Mood disorder diagnoses prior to hospitalization for COVID-19 was associated with increased risk of in-hospital mortality after Day 12. 2. Prior mood disorders were...

Post-COVID syndrome associated with significant morbidity and mortality beyond respiratory illnesses

1. Hospital readmission and all-cause mortality rates are 3.5 and 7.7 times higher in COVID-19 patients after discharge, than the general population. 2. In addition...

Tislelizumab plus chemotherapy vs chemotherapy alone as treatment for advanced squamous NSCLC

1. Tislelizumab, a monoclonal antibody and PD1/L1 inhibitor, when combined with chemotherapy, showed significantly prolonged progression free survival and higher objective response rate, compared...

3 days of β-lactam therapy is non-inferior to 8 days of therapy among patients...

1. Cure at 15 days occurred in 77% of patients in the placebo (3-day therapy) group compared to 68% of patients in the β-lactam...

Reinfection rates among patients previously testing positive for COVID-19

1. Among a large U.S. cohort, previous infection with SARS-CoV-2 appears to confer high levels of immunity against reinfection for at least 8 months. Evidence...

All-time hits